Patents by Inventor Christopher Boyce

Christopher Boyce has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11874280
    Abstract: Compositions comprising fluorescent or colored dyes and methods of using the same in combination with divalent metal salts to analyze samples are disclosed.
    Type: Grant
    Filed: March 8, 2019
    Date of Patent: January 16, 2024
    Assignee: Sony Group Corporation
    Inventors: Melissa Jackson, Christopher Boyce, Eriko Matsui, Michael Vanbrunt, Sharat Singh, Tracy Matray
  • Publication number: 20210109104
    Abstract: Compositions comprising fluorescent or colored dyes and methods of using the same in combination with divalent metal salts to analyze samples are disclosed.
    Type: Application
    Filed: March 8, 2019
    Publication date: April 15, 2021
    Inventors: Melissa JACKSON, Christopher BOYCE, Eriko MATSUI, Michael VANBRUNT, Sharat SINGH, Tracy MATRAY
  • Patent number: 10011615
    Abstract: Disclosed are compounds of Formula G1: where “RG3”. “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein, which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
    Type: Grant
    Filed: February 2, 2017
    Date of Patent: July 3, 2018
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
  • Patent number: 9926601
    Abstract: The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.
    Type: Grant
    Filed: February 24, 2012
    Date of Patent: March 27, 2018
    Assignees: Massachusetts Institute of Technology, Montefiore Medical Center, Albert Einstein College of Medicine, Inc.
    Inventors: Frank B. Gertler, Christopher Boyce Burge, Irina M. Shapiro, Wu Albert Cheng, John S. Condeelis, Maja H. Oktay
  • Patent number: 9884048
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.
    Type: Grant
    Filed: December 10, 2015
    Date of Patent: February 6, 2018
    Assignee: MERCK SHARP & DOHME CORP.
    Inventors: Phieng Siliphaivanh, Joey Methot, Kathryn Ann Lipford, Danielle Molinari, David L. Sloman, David Witter, Hua Zhou, Christopher Boyce, Xianhai Huang, Jongwon Lim, David Guerin, Ganesh Babu Karunakaran, Raman Kumar Bakshi, Ziping Liu, Jianmin Fu, Zhilong Wan, Wei Liu
  • Publication number: 20170266167
    Abstract: The present invention provides a compound of Formula (I) or the pharmaceutically acceptable salts, esters, and prodrugs thereof, which are ERK2 inhibitors. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and a pharmaceutically acceptable carrier. The invention also provides a pharmaceutical composition comprising an effective amount of at least one compound of Formula (I) and an effective amount of at least one other pharmaceutically active ingredient (such as, for example, a chemotherapeutic agent), and a pharmaceutically acceptable carrier.
    Type: Application
    Filed: December 10, 2015
    Publication date: September 21, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Phieng Siliphaivanh, Joey Methot, Kathryn Ann Lipford, Danielle Molinari, David L. Sloman, David Witter, Hua Zhou, Christopher Boyce, Xianhai Huang, Jongwon Lim, David Guerin, Ganesh Babu Karunakaran, Raman Kumar Bakshi, Ziping Liu, Jianmin Fu, Zhilong Wan, Wei Liu
  • Publication number: 20170197991
    Abstract: Disclosed are compounds of Formula G1: where “RG3”. “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein, which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2A receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
    Type: Application
    Filed: February 2, 2017
    Publication date: July 13, 2017
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
  • Patent number: 9676780
    Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
    Type: Grant
    Filed: December 20, 2013
    Date of Patent: June 13, 2017
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Michael Berlin, Pauline Ting, Gang Zhou, Tao Yu, Christopher Boyce, Joseph Michael Kelly, Jayaram R. Tagat, Junying Zheng, Xianhai Huang, Wei Zhou, Jae-Hun Kim, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Rajan Anand, Qiaolin Deng
  • Patent number: 9513175
    Abstract: An apparatus for spatially correcting an image frame is disclosed. In some embodiments, the apparatus stores a frame of pixel values and scans a multi-pixel correction window across the frame. Spatial correction is performed on pixels within the window at correction positions during the scan. The spatial correction comprises estimating pixel values at value estimation positions based on one or more pixel values within the window for pixels satisfying a logical condition. The value estimation positions correspond to pixel values which do not fall within the window again during the scan. Further disclosed is an apparatus for detecting high-energy radiation, in which integration circuitry is used for integrating charge responsive to radiation photon interaction events. The circuits are controllable in accordance with an exposure control signal to vary an exposure window duration according to an operating parameter of the apparatus.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: December 6, 2016
    Assignee: RADIATION WATCH LIMITED
    Inventors: David Prendergast, Michael Anderson, Paul Downes, William Croydon, Christopher Boyce, Wayne Cranwell, Trevor McAlister, Zhuo Zhhang
  • Publication number: 20160313456
    Abstract: An apparatus for spatially correcting an image frame is disclosed. In some embodiments, the apparatus stores a frame of pixel values and scans a multi-pixel correction window across the frame. Spatial correction is performed on pixels within the window at correction positions during the scan. The spatial correction comprises estimating pixel values at value estimation positions based on one or more pixel values within the window for pixels satisfying a logical condition. The value estimation positions correspond to pixel values which do not fall within the window again during the scan. Further disclosed is an apparatus for detecting high-energy radiation, in which integration circuitry is used for integrating charge responsive to radiation photon interaction events. The circuits are controllable in accordance with an exposure control signal to vary an exposure window duration according to an operating parameter of the apparatus.
    Type: Application
    Filed: June 3, 2016
    Publication date: October 27, 2016
    Inventors: David Prendergast, Michael Anderson, Paul Downes, William Croydon, Christopher Boyce, Wayne Cranwell, Trevor McAlister, Zhuo Zhhang
  • Publication number: 20160194330
    Abstract: Disclosed are compounds of Formula A: (structurally represented) where “RG1”, “RG2a”, “RG4”, “RG5”, “MG1”, “n” and “m” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
    Type: Application
    Filed: December 20, 2013
    Publication date: July 7, 2016
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Michael Berlin, Pauline Ting, Gang Zhou, Tao Yu, Christopher Boyce, Joseph Michael Kelly, Jayaram R. Tagat, Junying Zheng, Xianhai Huang, Wei Zhou, Jae-Hun Kim, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Rajan Anand, Qiaolin Deng
  • Patent number: 9233979
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: January 12, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin J. Wilson, David J. Witter, Phieng Siliphaivanh, Kathryn Lipford, David Sloman, Danielle Falcone, Brendan O'Boyle, Umar Faruk Mansoor, Jongwon Lim, Joey L. Methot, Christopher Boyce, Lei Chen, Matthew H. Daniels, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Ling Tong, Wei Zhou, Joseph Kozlowski, Milana M. Maletic, Bidhan A. Shinkre, Jayanth Thiruvellore Thatai, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • Patent number: 9226922
    Abstract: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).
    Type: Grant
    Filed: September 26, 2013
    Date of Patent: January 5, 2016
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Kevin J. Wilson, David J. Witter, Matthew H. Daniels, Angie R. Angeles, Phieng Siliphaivanh, David Sloman, Brendan O'Boyle, Danielle Falcone, Catherine White, Ron Ferguson, Wei Zhou, Kathryn Lipford, Umar Faruk Mansoor, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Judson E. Richard, Shuyi Tang, Christopher Boyce, Joseph Kozlowski, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • Publication number: 20150361098
    Abstract: Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.
    Type: Application
    Filed: December 20, 2013
    Publication date: December 17, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Amjad Ali, Michael Man-Chu Lo, Yeon-Hee Lim, Andrew Stamford, Rongze Kuang, Paul Tempest, Younong Yu, Xianhai Huang, Timothy J. Henderson, Jae-Hun Kim, Christopher Boyce, Pauline Ting, Junying Zheng, Edward Metzger, Nicolas Zorn, Dong Xiao, Gioconda V. Gallo, Walter Won, Heping Wu, Qiaolin Deng
  • Publication number: 20150266895
    Abstract: Disclosed are the ERK inhibitors of formula (1): and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1).
    Type: Application
    Filed: September 26, 2013
    Publication date: September 24, 2015
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: Kevin J. Wilson, David J. Witter, Phieng Siliphaivanh, Kathryn Lipford, David Sloman, Danielle Falcone, Brendan O'Boyle, Umar Faruk Mansoor, Jongwon Lim, Joey L. Methot, Christopher Boyce, Lei Chen, Matthew H. Daniels, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Ling Tong, Wei Zhou, Joseph Kozlowski, Milana M. Maletic, Bidhan A. Shinkre, Jayanth Thiruvellore Thatai, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • Publication number: 20150258074
    Abstract: Disclosed are the ERK inhibitors of formula (1.0), having a pyrazolopyridine base structure, and the pharmaceutically acceptable salts thereof. Also disclosed are methods of treating cancer using the compounds of formula (1.0).
    Type: Application
    Filed: September 26, 2013
    Publication date: September 17, 2015
    Applicant: MERCK SHARP & DOHME CORP.
    Inventors: Kevin J. Wilson, David J. Witter, Matthew H. Daniels, Angie R. Angeles, Phieng Siliphaivanh, David Sloman, Brendan O'Boyle, Danielle Falcone, Catherine White, Ron Ferguson, Wei Zhou, Kathryn Lipford, Umar Faruk Mansoor, Salem Fevrier, Xianhai Huang, Ravi Kurukulasuriya, Judson E. Richard, Shuyi Tang, Christopher Boyce, Joseph Kozlowski, Raman Kumar Bakshi, Ganesh Babu Karunakaran
  • Publication number: 20150083925
    Abstract: An apparatus for spatially correcting an image frame is disclosed. In some embodiments, the apparatus stores a frame of pixel values and scans a multi-pixel correction window across the frame. Spatial correction is performed on pixels within the window at correction positions during the scan. The spatial correction comprises estimating pixel values at value estimation positions based on one or more pixel values within the window for pixels satisfying a logical condition. The value estimation positions correspond to pixel values which do not fall within the window again during the scan. Further disclosed is an apparatus for detecting high-energy radiation, in which integration circuitry is used for integrating charge responsive to radiation photon interaction events. The circuits are controllable in accordance with an exposure control signal to vary an exposure window duration according to an operating parameter of the apparatus.
    Type: Application
    Filed: April 30, 2014
    Publication date: March 26, 2015
    Applicant: RADIATION WATCH LIMITED
    Inventors: David Prendergast, Michael Anderson, Paul Downes, William Croydon, Christopher Boyce, Wayne Cranwell, Trevor McAlister, Zhuo Zhhang
  • Publication number: 20140066319
    Abstract: The present invention provides a method for identifying a tumor as likely to metastasize, or likely to have metastasized, comprising obtaining a sample of the tumor and quantitating alternatively spliced mRNA isoforms of a cell motility gene, a cell adhesion gene and/or an actin cytoskeletal remodeling gene in the sample, or any specified genes or the level of RNA binding proteins compared to a predetermined non-metastasizing control.
    Type: Application
    Filed: February 24, 2012
    Publication date: March 6, 2014
    Applicants: Massachusetts Institute of Technology, Montefiore Medical Center, Albert Einstein College of Medicine of Yeshiva University
    Inventors: Frank B. Gertler, Christopher Boyce Burge, Irina M. Shapiro, Wu Albert Cheng, John S. Condeelis, Maja H. Oktay
  • Patent number: 8335515
    Abstract: A communications system includes remote stations coupled to a central station by a network. The system includes the network, the central station establishes a list of information about available network resources and publishes the list for the remote station. The system includes the remote stations, which identify a set of said published resources needed to establish the connection, notify the central station about the identified resources, and seize the set of identified resources to thereby establish the connection. The central station updates the list of available resources to thereby reflect the seizing of the set, and communicates the updated list to the remote stations.
    Type: Grant
    Filed: March 9, 2012
    Date of Patent: December 18, 2012
    Assignee: Thiss Technologies Pte Ltd
    Inventors: Thomas Earle Goerke, Richard Harold Hammersla, Nicholas Richard Hart, Christopher Boyce Meulman, Nicholas Antony Cirillo
  • Publication number: 20120230300
    Abstract: A communications system includes remote stations coupled to a central station by a network. The system includes the network, the central station establishes a list of information about available network resources and publishes the list for the remote station. The system includes the remote stations, which identify a set of said published resources needed to establish the connection, notify the central station about the identified resources, and seize the set of identified resources to thereby establish the connection. The central station updates the list of available resources to thereby reflect the seizing of the set, and communicates the updated list to the remote stations.
    Type: Application
    Filed: March 9, 2012
    Publication date: September 13, 2012
    Applicant: THISS TECHNOLOGIES PTE LTD
    Inventors: Thomas Earle Goerke, Richard Harold Hammersla, Nicholas Richard Hart, Christopher Boyce Meulman, Nicholas Antony Cirillo